PGIMER has developed a low-cost, indigenous High Flow Nasal Cannula (HFNC) device, TrueOxy+, designed to provide non-invasive respiratory support to patients in intensive care units who are experiencing breathing difficulties or low oxygen levels. Conceived and developed entirely at the institute, the device was created under a Department of Science and Technology–supported research project aimed at offering an affordable, high-quality “Made in India” alternative for treating acute hypoxemic respiratory failure and similar conditions.
The TrueOxy+ system can deliver oxygen at flow rates of up to 60 litres per minute, with adjustable oxygen concentration ranging from 21% to 100% and temperature control between 31°C and 37°C. It also features integrated monitoring, an advanced alarm system, and multiple patient-safety safeguards aligned with international standards. The device was tested extensively for more than a year at PGIMER’s Biomedical Hub before being evaluated in a Phase-1 clinical trial at the institute in 2024.
